Genmab A/S
CSE:GMAB
Genmab A/S
Total Equity
Genmab A/S
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Total Equity
kr5.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
28%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Equity
kr14.8B
|
CAGR 3-Years
163%
|
CAGR 5-Years
65%
|
CAGR 10-Years
50%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Total Equity
$15.8m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Equity
-€162.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Equity
kr13.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
20%
|
CAGR 10-Years
26%
|
|
|
Saniona AB
STO:SANION
|
Total Equity
kr635.2m
|
CAGR 3-Years
129%
|
CAGR 5-Years
1%
|
CAGR 10-Years
28%
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Total Equity?
Total Equity
5.8B
DKK
Based on the financial report for Dec 31, 2025, Genmab A/S's Total Equity amounts to 5.8B DKK.
What is Genmab A/S's Total Equity growth rate?
Total Equity CAGR 10Y
28%
Over the last year, the Total Equity growth was 15%. The average annual Total Equity growth rates for Genmab A/S have been 14% over the past three years , 13% over the past five years , and 28% over the past ten years .
